Impact BioMedical, Inc. (IBO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Impact BioMedical, Inc. stock (IBO) is currently trading at $0.58. Impact BioMedical, Inc. PS ratio (Price-to-Sales) is 2628.14. WallStSmart rates IBO as Sell.
- IBO PE ratio analysis and historical PE chart
- IBO PS ratio (Price-to-Sales) history and trend
- IBO intrinsic value — DCF, Graham Number, EPV models
- IBO stock price prediction 2025 2026 2027 2028 2029 2030
- IBO fair value vs current price
- IBO insider transactions and insider buying
- Is IBO undervalued or overvalued?
- Impact BioMedical, Inc. financial analysis — revenue, earnings, cash flow
- IBO Piotroski F-Score and Altman Z-Score
- IBO analyst price target and Smart Rating
Impact BioMedical, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Impact BioMedical, Inc. (IBO) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Impact BioMedical, Inc. (IBO) Key Strengths (0)
Impact BioMedical, Inc. (IBO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 2628.1x annual revenue
Very expensive at 6.7x book value
Very low institutional interest at 1.33%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Impact BioMedical, Inc. (IBO) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (2628.14), Price/Book (6.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -104.20%, Operating Margin at -16543.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -104.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IBO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IBO's Price-to-Sales ratio of 2628.14x trades 320% above its historical average of 625.07x (92th percentile), historically expensive. The current valuation is 7% below its historical high of 2813.89x set in Mar 2026, and 13440% above its historical low of 19.41x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~68.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Impact BioMedical, Inc. (IBO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Impact BioMedical, Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Generating 99,000 in free cash flow and 99,000 in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of -1.94 indicates a conservative balance sheet with 12,000 in cash.
What to Watch Next
Debt management: total debt of 23M is significantly higher than cash (12,000). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Impact BioMedical, Inc..
Bottom Line
Impact BioMedical, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 2:34:40 PM
About Impact BioMedical, Inc.(IBO)
AMEX
HEALTHCARE
BIOTECHNOLOGY
USA
Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Leveraging advanced research and development techniques, the firm seeks to improve health outcomes and enhance the overall quality of life for patients. With a robust intellectual property portfolio and a commitment to scientific rigor, Impact BioMedical is well-positioned for substantial growth in the evolving healthcare market. Its expanding product pipeline and strategic collaborations offer attractive opportunities for institutional investors looking to capitalize on transformative developments within the biopharmaceutical sector.